pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,587 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1020Endpoints769BioPharma Dive293BioSpace210Fierce Biotech198onclive165raps74globenewswire health
therapy area
allOncology5950Rare Disease1401Cardiology1087Hematology1008Immunology991Pulmonology892Vaccines
  • US and UK health systems both prioritize clinical care over community prevention, author warns
    Kyle Vanelli argues that the United States and United Kingdom health systems share a fundamental flaw: they default to biomedical, hospital-based interventions rather than community-based preventiv…
    STAT · 6d agoNegative↗ source
  • CMS rule blocks Medicaid funding for pediatric gender-affirming care, raising legal challenges
    The Centers for Medicare and Medicaid Services finalized a rule that prohibits the use of Medicaid and CHIP dollars to cover pediatric gender‑affirming medications and surgeries. Previous attempts…
    STAT · 6d agoRegulatoryNeutral↗ source
← prev
page 4 of 64
next →
73
fda recalls47
fda medwatch36
fda press28
885
Psychiatry & CNS710
Ophthalmology419
Endocrinology & Metabolism377
Pain371
Infectious Disease346
  • Pediatricians push back against vaccine fear-mongering by federal leaders
    Andrew D. Racine, president of the American Academy of Pediatrics, writes an opinion piece warning that federal leaders are spreading misleading claims about vaccines, creating confusion for parent…
    STAT · 5d agoNegative↗ source
  • Formation Bio appoints Michael Ehlers as chief scientific officer and head of R&D
    Formation Bio announced the hiring of Michael Ehlers as its new chief scientific officer and head of research and development. Ehlers brings experience from founding and leading Ascidian Therapeut…
    STAT · 5d agoPositive↗ source
  • Opinion: Car telematics warns of health-insurance data surveillance
    Sociologists Andréa Becker and Paul Kamuf argue that the telematics model used in auto insurance could become a template for health‑insurance data collection. They describe how drivers’ minute‑by‑…
    STAT · 6d agoNegative↗ source
  • Taiho and Cullinan report positive Phase 3 results for zipalertinib in EGFR exon 20 insertion lung cancer
    Taiho Oncology and Cullinan Therapeutics announced that their experimental drug zipalertinib achieved positive results in a Phase 3 trial for first‑line treatment of lung cancer patients whose tumo…
    BioPharma Dive · 6d agoPositive readoutPositive↗ source
  • Neurocrine’s rare-disease drug approved but later linked to deaths and serious side effects
    Neurocrine Biosciences received regulatory approval for a rare‑disease therapy after a small clinical trial showed modest efficacy and side effects that were considered manageable. The decision was…
    STAT · 7d agoRegulatoryNegative↗ source
  • PTC Therapeutics agrees to pay up to $211 million for Sangamo’s experimental Fabry disease gene therapy
    PTC Therapeutics announced it will invest up to $211 million to acquire rights to an advanced gene therapy for Fabry disease being developed by Sangamo Therapeutics. The therapy, called ST-920 (is…
    BioPharma Dive · 6d agoDealNeutral↗ source
  • California distributes over 120,000 low-cost insulin glargine packs as Novo Nordisk CEO warns investors on obesity drug differentiation
    California's state health program has been distributing a low-cost insulin glargine product, more than 120,000 five-pen packs since its launch seven months ago. Each pack is priced at $55, which i…
    STAT · 6d agoNeutral↗ source
  • Oxford study offers model showing statins pose minimal muscle disorder risk, a tool against health misinformation
    The piece highlights how fearmongering about statins has surged online, with claims that the drugs damage the brain, liver and muscles. The authors argue that clearer evidence at the point of claim…
    STAT · 7d agoPositive↗ source
  • Vaccines protect lives: A physician’s reminder of what we lose without them
    Dr. Krutika Kuppalli, an infectious-disease physician and former WHO medical officer, reflects on her frontline work where vaccines were scarce. In Haiti she witnessed a patient die from tetanus,…
    STAT · 7d agoPositive↗ source
  • Medicare's new add-on payments for AI devices may spur hospital adoption and risk overuse
    Medicare has begun paying hospitals extra fees for using newly authorized AI-based medical devices, known as technology add-on payments, for a limited period after market entry. The payments are i…
    STAT · 7d agoRegulatoryNeutral↗ source
  • Eli Lilly moves to curb black-market sales of retatrutide amid rising illicit demand
    Eli Lilly announced steps to address the growing black‑market trade of its obesity/diabetes drug retatrutide, which has seen increasing illicit use. The company is working with law‑enforcement and…
    STAT · 6d agoRegulatoryNegative↗ source
  • New fertility options give young cancer survivors hope for parenthood
    Young cancer patients are facing increasing concerns about future fertility, prompting the growth of a specialty called oncofertility that blends oncology and reproductive medicine. One patient, J…
    STAT · 7d agoPositive↗ source
  • Baxter recalls Duo-Vent IV solution sets over risk of air bubbles in patients
    Baxter has issued a recall of its Duo-Vent solution sets and male Luer lock adapters after the FDA identified a risk that the devices could contain air bubbles in the drip chamber and tubing. The…
    fda medwatch · 7d agoCRLNegative↗ source
  • STAT+ probes Commure’s AI-driven health-care platform and Medicare’s new incentives for AI medical devices
    The STAT Health Tech newsletter edition dated Aug 13, 2026 features an investigative piece on Commure, a General Catalyst-backed firm that claims to automate health-care operations using artificial…
    STAT · 6d agoNeutral↗ source
  • California’s new CalRx insulin label aims for affordable access but faces slow rollout
    California launched a state‑branded insulin label, CalRx, this year to provide lower‑cost insulin to patients without insurance. The pens, marked with the state’s grizzly bear logo, are now stocked…
    STAT · 7d agoNeutral↗ source
  • Health secretary Kennedy pushes new addiction-treatment strategy in California, criticizes prior administration
    Health secretary Robert F. Kennedy Jr. traveled to California to present the Biden administration’s revised plan for addiction treatment, following a recent White House initiative on vaccine policy…
    STAT · 6d agoRegulatoryNeutral↗ source
  • Patients with treatment-resistant depression weigh pros and cons of brain-implant devices
    A new study surveyed individuals with treatment-resistant depression about their preferences and concerns regarding implantable brain devices aimed at alleviating mood symptoms. Respondents highli…
    STAT · 7d agoNeutral↗ source
  • Commure ends referral payment program for its AI clinic tools
    Commure, a health-software firm valued at about $7 billion, announced it is ending the referral-payment arrangements it had with partners who promoted its artificial-intelligence products to medica…
    STAT · 6d agoNeutral↗ source
  • Definium's LSD pill shows positive results in late-stage anxiety trial
    Definium Therapeutics reported that its pharmaceutical-grade LSD formulation, DT120, achieved positive outcomes in a late-stage study targeting generalized anxiety disorder. The trial used a 56-po…
    BioPharma Dive · 7d agoPositive readoutPositive↗ source
  • Study finds cancer patients now wait longer for treatment than a decade ago
    A new analysis of more than 2.7 million cancer cases shows that the interval between diagnosis and the start of therapy has grown over the past ten years. The researchers examined records from a na…
    STAT · 7d agoNegative↗ source
  • Neurocrine's Prader-Willi drug Vykat XR linked to multiple deaths and serious side effects
    A group of physicians and experts in Prader-Willi syndrome warned clinicians about safety concerns with Vykat XR, a drug approved by the FDA in March 2025 to reduce the intense hunger in patients w…
    STAT · 8d agoRegulatoryNegative↗ source
  • Definium's LSD pill shows significant anxiety reduction in Phase 3 trial
    Definium Therapeutics announced results of a Phase 3 trial testing its LSD‑based pill DT120 in patients with generalized anxiety disorder. The study enrolled 214 participants who received a single…
    STAT · 7d agoPositive readoutPositive↗ source
  • WHO and DRC move to fast-track Phase 3 Ebola vaccine trial, starting with Merck’s Ervebo
    The World Health Organization and authorities in the Democratic Republic of the Congo are negotiating to speed up the launch of a multi‑armed Phase 3 trial of Ebola vaccines. The effort targets th…
    STAT · 7d agoCRLPositive↗ source